Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dolutegravir - ViiV Healthcare

Drug Profile

Dolutegravir - ViiV Healthcare

Alternative Names: '572; 1349572; Dolutegravir sodium; DTG; GSK-1349572; S-349572; S/GSK 1349572; Tivicay

Latest Information Update: 03 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi-GlaxoSmithKline Pharmaceuticals
  • Developer Bellvitge University Hospital; GlaxoSmithKline; INSERM; National Institute of Allergy and Infectious Diseases; Shionogi-GlaxoSmithKline Pharmaceuticals; University of Liverpool; ViiV Healthcare
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Oxazines; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections
  • Phase III HIV infections

Most Recent Events

  • 25 Jul 2019 ViiV Healthcare completes a phase I trial in HIV infections (In volunteers, In adults) in United Kingdom (PO, Fast dissolve, Liquid, Suspension) (NCT03921723)
  • 19 Apr 2019 ViiV Healthcare plans a phase I trial for HIV infections (In volunteers) in United Kingdom (PO, Suspension, Liquid) (NCT03921723)
  • 07 Mar 2019 Pharmacodynamics data from a phase I trial in Healthy volunteers presented at the 26th Conference on Retroviruses and Opportunistic Infections (CROI-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top